Phase II and UGT1A1 Polymorphism Study of Two Different Irinotecan Dosages Combined with Cisplatin as First-Line Therapy for Advanced Gastric Cancer

Publisher： Karger

E-ISSN： 1421-9794|61|4|197-203

ISSN： 0009-3157

Source： Chemotherapy, Vol.61, Iss.4, 2016-02, pp. : 197-203

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase II Study of Capecitabine plus Oxaliplatin as First-Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer

By  

Chemotherapy, Vol. 58, Iss. 1, 2012-02 ,pp. : 1-7

Karger

Access to resources Recommend Favorite

Prospective Phase II Trial of Gemcitabine in Combination with Irinotecan as First-Line Chemotherapy in Patients with Advanced Biliary Tract Cancer

By  

Chemotherapy, Vol. 57, Iss. 3, 2011-05 ,pp. : 236-243

Karger

Access to resources Recommend Favorite

Phase I/II Trial of Irinotecan and S-1 Combination Chemotherapy as a Second-Line Treatment for Advanced Colorectal Cancer

By  

Chemotherapy, Vol. 59, Iss. 5, 2014-05 ,pp. : 338-343

Karger

Access to resources Recommend Favorite

Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer

By  

Chemotherapy, Vol. 56, Iss. 2, 2010-03 ,pp. : 94-100

Karger

Access to resources Recommend Favorite

Irinotecan Combined with Infusional 5-Fluorouracil and High-Dose Leucovorin for the Treatment of Advanced Gastric Carcinoma as the First-Line Chemotherapy

By  

Chemotherapy, Vol. 52, Iss. 5, 2006-08 ,pp. : 264-270

Karger

Access to resources Recommend Favorite